T-cell proliferation assay for the detection of SARS-CoV-2-specific T-cells
Both infection with and vaccination against SARS-CoV-2 trigger a complex B-cell and T-cell response. Methods for the analysis of the B-cell response are now well established. However, reliable methods for measuring the T-cell response are less well established and their usefulness in clinical settin...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
1 July 2022
|
| In: |
Clinica chimica acta
Year: 2022, Jahrgang: 532, Pages: 130-136 |
| ISSN: | 1873-3492 |
| DOI: | 10.1016/j.cca.2022.05.025 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.cca.2022.05.025 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0009898122011780 
|
| Verfasserangaben: | Chang Chu, Anne Schönbrunn, Saban Elitok, Florian Kern, Karsten Schnatbaum, Holger Wenschuh, Kristin Klemm, Volker von Baehr, Bernhard K. Krämer, Berthold Hocher |
| Zusammenfassung: | Both infection with and vaccination against SARS-CoV-2 trigger a complex B-cell and T-cell response. Methods for the analysis of the B-cell response are now well established. However, reliable methods for measuring the T-cell response are less well established and their usefulness in clinical settings still needs to be proven. Here, we have developed and validated a T-cell proliferation assay based on 3H thymidine incorporation. The assay is using SARS-CoV-2 derived peptide pools that cover the spike (S), the nucleocapsid (N) and the membrane (M) protein for stimulation. We have compared this novel SARS-CoV-2 lymphocyte transformation test (SARS-CoV-2 LTT) to an established ELISA assay detecting Immunoglobulin G (IgG) antibodies to the S1 subunit of the SARS-CoV-2 spike protein. The study was carried out using blood samples from both vaccinated and infected health care workers as well as from a non-infected control group. Our novel SARS-CoV-2 LTT shows excellent discrimination of infected and/or vaccinated individuals versus unexposed controls, with the ROC analysis showing an area under the curve (AUC) of > 0.95. No false positives were recorded as all unexposed controls had a negative LTT result. When using peptide pools not only representing the S protein (found in all currently approved vaccines) but also the N and M proteins (not contained in the vast majority of vaccines), the novel SARS-CoV-2 LTT can also discriminate T-cell responses resulting from vaccination against those induced by infection. |
|---|---|
| Beschreibung: | Online verfügbar: 8 June 2022, Artikelversion: 9 June 2022 Gesehen am 21.11.2023 |
| Beschreibung: | Online Resource |
| ISSN: | 1873-3492 |
| DOI: | 10.1016/j.cca.2022.05.025 |